AAA_Logo_Final_RGB.jpg
Advanced Accelerator Applications Announces Health Canada Approval for Lutathera™, a Treatment for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)¹
07 févr. 2019 07h00 HE | Advanced Accelerator Applications
First ever approved Peptide Receptor Radionuclide Therapy in CanadaNeuroendocrine tumors are rare malignancies that affect approximately 12,000-15,000 Canadians2 SAINT-GENIS-POUILLY, France, Feb. ...
AAA_Logo_Final_RGB.jpg
Advanced Accelerator Applications signs exclusive option and license agreement with FUJIFILM Toyama Chemical to develop and commercialize radiolabeled FF-10158 for oncology indications
03 déc. 2018 03h00 HE | Advanced Accelerator Applications
Novel small molecule FF-10158 targets integrin alphavbeta3 (avβ3) and alphavbeta5 (avβ5) receptors Expands theragnostic pipeline  Potential broad application in the detection and treatment of highly...
AAA_Logo_Final_RGB.jpg
Advanced Accelerator Applications Signs Exclusive License Agreement with Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer
12 févr. 2018 07h00 HE | Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a Novartis company and leader in nuclear medicine...
AAA_Logo_Final_RGB.jpg
Advanced Accelerator Applications Announces Completion of Subsequent Offering Period for Novartis Tender Offer
01 févr. 2018 16h05 HE | Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or the “Company”), a Novartis company and a leader in nuclear medicine...
Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
26 janv. 2018 12h00 HE | Advanced Accelerator Applications
First-in-class Therapy Demonstrated 79% Improvement in Progression Free Survival in NETTER-1 Phase 3 Study in Midgut NET Patients LUTATHERA® marks first FDA Approval for a Peptide Receptor...
AAA_Logo_Final_RGB.jpg
Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer
22 janv. 2018 08h00 HE | Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or the “Company”), a leader in nuclear medicine theragnostics, today...
AAA_Logo_Final_RGB.jpg
Advanced Accelerator Applications Announces Commencement of Novartis Tender Offer
07 déc. 2017 07h00 HE | Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced...
AAA_Logo_Final_RGB.jpg
Advanced Accelerator Applications Board of Directors Recommends $3.9 Billion All Cash Tender Offer by Novartis
05 déc. 2017 16h00 HE | Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced...
AAA_Logo_Final_RGB.jpg
Advanced Accelerator Applications Reports 39% Sales Growth for Third Quarter 2017
17 nov. 2017 07h39 HE | Advanced Accelerator Applications
$3.9 Billion All Cash Proposed Tender Offer by Novartis European Approval of Lutetium Lu 177 Dotatate* (Lutathera®) for GEP-NETs Recent Highlights: Sales for the third quarter of 2017 increased 39%...
AAA_Logo_Final_RGB.jpg
Advanced Accelerator Applications Announces $3.9 Billion All Cash Proposed Tender Offer by Novartis
30 oct. 2017 02h00 HE | Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced...